发炎性肠道疾病市场按药物类别、适应症、给药途径、分销管道和地区划分

2025 年全球发炎性肠道疾病市场规模估计为 233.4 亿美元，预计到 2032 年将达到 320 亿美元，2025 年至 2032 年的复合年增长率为 4.6%。

数字。 2025 年发炎性肠道疾病市场占有率（按地区划分）

发炎性肠道疾病肠道疾病(IBD) 是指两种疾病－克隆氏症和溃疡性大肠炎－其特征是消化道慢性发炎。 IBD 主要影响小肠和大肠，但有时会扩散到消化器官系统的其他部位。 IBD 的典型症状因患者而异，但通常包括反覆腹痛、腹泻、呕吐、体重减轻和疲劳。儘管确切的原因尚不清楚，但人们认为 IBD 是在遗传易感个体对环境触发因素的免疫反应调节不当而发生的。目前可用的治疗方法旨在透过针对免疫系统的不同组成部分来诱导和维持缓解。由于这些治疗方法无法治癒IBD，因此IBD在世界范围内仍然是一个沉重的临床和经济负担。

市场动态

全球发炎性肠道疾病市场的发展主要受到生活方式改变、环境风险增加和已开发国家预期寿命增加导致克隆氏症和溃疡性大肠炎盛行率上升的推动。此外，致力于开发新型选择性和个人化疗法的研究和开发不断增加、对 IBD 早期诊断和管理的认识不断提高以及主要市场的医疗保健支出不断增加也在推动市场成长。然而，严格的药物开发法规以及与 IBD 诊断工具和药物相关的高成本可能会阻碍市场的成长。生技药品、干细胞、基因治疗等领域的先进研究和开发可能为相关人员提供丰厚的机会。

研究的主要特点

• 本报告对全球发炎性肠道疾病市场进行了详细分析，并提供了预测期（2025-2032 年）的市场规模（十亿美元）和年复合成长率（CAGR%），假设基准年为 2024 年。
• 它还强调了各个领域的潜在商机并说明了该市场的有吸引力的投资提案矩阵。
• 它还提供了对市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景以及主要企业采用的竞争策略的重要见解。
• 本报告的见解将使负责人和企业经营团队能够就未来产品发布、高端市场策略、市场扩张和行销策略做出明智的决策。
• 全球发炎性肠道疾病市场报告迎合了该行业的各个相关人员，例如投资者、供应商、产品製造商、经销商、新进入者和金融分析师。
• 相关人员将透过全球发炎性肠道疾病市场分析中使用的各种策略矩阵更轻鬆地做出决策。

目录

第一章 调查目的与前提条件

• 研究目标
• 先决条件
• 简称

第二章 市场展望

• 报告描述
  • 市场定义和范围
• 执行摘要
• 一致的机会图 (COM)

第三章市场动态、法规与趋势分析

• 市场动态
  • 驱动程式
  • 限制因素
  • 机会
• 影响分析
• 市场趋势
• 监管情景
• 收购和合作场景
• 资金筹措和投资
• PEST分析
• 波特的分析

4. 全球发炎性肠道疾病市场 - 冠状病毒 (COVID-19) 大流行的影响

• 整体影响
• 政府倡议
• COVID-19 市场影响

5. 2020 年至 2032 年全球发炎性肠道疾病市场（按药物类别划分）（十亿美元）

• 介绍
• 皮质类固醇
• 胺基水杨酸
• TNF 抑制剂
• 免疫抑制剂
• 抗生素
• 其他的

6. 2020 年至 2032 年全球发炎性肠道疾病市场（依适应症划分）（十亿美元）

• 介绍
• 溃疡性大肠炎
• 克隆氏症

7. 2020 年至 2032 年全球发炎性肠道疾病市场，依给药途径划分（十亿美元）

• 介绍
• 口服
• 注射

8. 2020-2032 年全球发炎性肠道疾病市场按分销管道划分（十亿美元）

• 介绍
• 医院药房
• 零售药局
• 网路药局

9. 2020 年至 2032 年全球发炎性肠道疾病市场（按地区划分）（十亿美元）

• 介绍
• 北美洲
• 拉丁美洲
• 欧洲
• 亚太地区
• 中东
• 非洲

第十章 竞争格局

• 公司简介
  • AbbVie Inc.
  • Johnson & Johnson Services, Inc.
  • Takeda Pharmaceutical Company Limited
  • Biogen
  • Amgen Inc.
  • UCB SA
  • Novartis AG
  • Merck &Co., Inc.
  • Pfizer Inc.
  • Eli Lilly and Company
  • Gilead Sciences
  • Bausch Health Companies Inc.
  • Celltrion Healthcare Co., Ltd.
  • CELGENE CORPORATION
  • COSMO PHARMACEUTICALS
  • Innovate Biopharmaceuticals
  • Sandoz
  • Horizon Therapeutics

第 11 章 分析师建议

• 兴衰
• 一致的机会地图

第 12 章参考文献与调查方法

• 参考
• 调查方法

Global Inflammatory Bowel Disease Market is estimated to be valued at USD 23.34 Bn in 2025 and is expected to reach USD 32.00 Bn by 2032, growing at a compound annual growth rate (CAGR) of 4.6% from 2025 to 2032.

Figure. Inflammatory Bowel Disease Market Share (%), By Region 2025

Inflammatory bowel disease (IBD) refers to two conditions - Crohn's disease and ulcerative colitis - that are characterized by chronic inflammation within the gastrointestinal tract. IBD predominantly affects the small and large intestines but can sometimes extend throughout other areas of the digestive system. Typical symptoms of IBD vary between patients but often include recurring abdominal pain, diarrhea, vomiting, weight loss, and fatigue. While the precise etiologies remain unclear, IBD is believed to arise due to inappropriately regulated immune responses to environmental triggers in genetically susceptible individuals. Currently available treatment options aim to induce and maintain remission by targeting different components of the immune system. As these approaches are not curative, IBD poses a substantial clinical and economic burden worldwide.

Market Dynamics:

Global inflammatory bowel disease market growth is primarily driven by rising prevalence of Crohn's disease and ulcerative colitis due to lifestyle changes, growing environmental risks, and prolonged lifespan in developed nations. Increasing research activities focused on developing novel selective and personalized therapies, growing awareness about early diagnosis and management of IBD, and rising healthcare expenditure across major markets can also drive the market growth. However, stringent drug development regulations and high costs associated with IBD diagnostic tools and medications can hamper the market growth. Ongoing R&D in biologics, stem cell and gene-based therapies can offer lucrative opportunities for stakeholders.

Key Features of the Study:

• This report provides in-depth analysis of the global inflammatory bowel disease market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• Key companies covered as a part of this study include AbbVie, Janssen Biotech, Takeda Pharmaceutical, UCB, and Pfizer
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global inflammatory bowel disease market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global inflammatory bowel disease market

Detailed Segmentation-

• By Drug Class
  • Corticosteroids
  • Aminosalicylates
  • TNF Inhibitors
  • Immunosuppressant
  • Antibiotics
  • Others
• By Disease Indication
  • Ulcerative Colitis
  • Crohn's Disease
• By Route of Administration
  • Oral
  • Injectable
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • AbbVie Inc.
  • Johnson & Johnson Services, Inc.
  • Takeda Pharmaceutical Company Limited
  • Biogen
  • Amgen Inc.
  • UCB S.A.
  • Novartis AG
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Eli Lilly and Company
  • Gilead Sciences
  • Bausch Health Companies Inc.
  • Celltrion Healthcare Co., Ltd.
  • CELGENE CORPORATION
  • COSMO PHARMACEUTICALS
  • Innovate Biopharmaceuticals
  • Sandoz
  • Horizon Therapeutics

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug Class
  • Market Snapshot, By Disease Indication
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Regulatory Scenario
• Acquisitions and Partnerships Scenario
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global Inflammatory Bowel Disease Market- Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the Market

5. Global Inflammatory Bowel Disease Market, By Drug Class, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Corticosteroids
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Aminosalicylates
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• TNF Inhibitors
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Immunosuppressant
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Antibiotics
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Inflammatory Bowel Disease Market, By Disease Indication, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Ulcerative Colitis
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Crohn's Disease
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Inflammatory Bowel Disease Market, By Route of Administration, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Oral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Injectable
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Inflammatory Bowel Disease Market, By Distribution Channel, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global Inflammatory Bowel Disease Market, By Region, 2020 - 2032, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region, 2020-2032
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Bn)
    • North Africa
    • Central Africa
    • South Africa

10. Competitive Landscape

• Company Profiles
  • AbbVie Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Johnson & Johnson Services, Inc.
  • Takeda Pharmaceutical Company Limited
  • Biogen
  • Amgen Inc.
  • UCB S.A.
  • Novartis AG
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Eli Lilly and Company
  • Gilead Sciences
  • Bausch Health Companies Inc.
  • Celltrion Healthcare Co., Ltd.
  • CELGENE CORPORATION
  • COSMO PHARMACEUTICALS
  • Innovate Biopharmaceuticals
  • Sandoz
  • Horizon Therapeutics

11. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

12. References and Research Methodology

• References
• Research Methodology
• About us and Sales Contact